ArticleOncoTargets and therapy2018
Article in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in the treatment of advanced colorectal cancer: a systematic review and meta-analysis.Frontiers in immunology · 2024Pooled it
- Pooled it
- Immunotherapy for colorectal cancer: insight from inherited genetics.Trends in cancer · 2024Review
- Article
- Finding the Common Single-Nucleotide Polymorphisms in Three Autoimmune Diseases and Exploring Their Bio-Function by Using a Reporter Assay.Biomedicines · 2023Article
- Evidence of Association between CTLA-4 Gene Polymorphisms and Colorectal Cancers in Saudi Patients.Genes · 2023Article
- Review
- Insilico prediction and functional analysis of nonsynonymous SNPs in human CTLA4 gene.Scientific reports · 2022Article
- Semi-automated validation and quantification of CTLA-4 in 90 different tumor entities using multiple antibodies and artificial intelligence.Laboratory investigation; a journal of technical methods and pathology · 2022Article
- Article
- Comprehensive Analysis of 29,464 Cancer Cases and 35,858 Controls to Investigate the Effect of the Cytotoxic T-Lymphocyte Antigen 4 Gene rs231775 A/G Polymorphism on Cancer Risk.Frontiers in oncology · 2022Article
- Identification and Verification of a 17 Immune-Related Gene Pair Prognostic Signature for Colon Cancer.BioMed research international · 2021Article
- Article
- The Influence ofJournal of clinical medicine · 2020Article
- Immune Checkpoint Molecules-Inherited Variations as Markers for Cancer Risk.Frontiers in immunology · 2020Review
- Investigation of BTLA tagging variants with risk of esophagogastric junction adenocarcinoma.Bioscience reports · 2019Article
- Association between methylenetetrahydrofolate reductase tagging polymorphisms and susceptibility of hepatocellular carcinoma: a case-control study.Bioscience reports · 2019Article
- Association ofJournal of clinical medicine · 2019Article
- Investigation of the Correlation between Graves' Ophthalmopathy and CTLA4 Gene Polymorphism.Journal of clinical medicine · 2019Article
- Cytotoxic T-lymphocyte Antigen-4 (In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPATIENTS AND
methodsTo determine the important role of
resultsThe findings suggested that CTLA-4 rs231775 G>A polymorphism increased the risk of CRC (homozygote model: adjusted OR=1.40, 95% CI=1.05-1.87,
conclusionThis study evidences an association of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.